Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New corporate presentation is on the website

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 16, 2021 10:15am

63 Views

Post# 33010352

RE:New corporate presentation is on the website

Seems to me they are re-emphasizing HIV NASH again (were they calling it "general and HIV NASH" before???). "Assessing EMA strategy" seems far more vague than their strat with the FDA, it doesn't even necessarily suggest there is a concrete interactive process going on with a defined targeted outcome (I feel much more confident that is what is happening with the FDA). My overactive imagination immediately went to a dual strat of targeting HIV NASH in Europe, to get the drug on the market in some form, bypassing whatever is troubling the EMA atm, and a general/HIV strat in the US. Seems fanciful though. Wouldn't stop expanding into general NASH in Europe at a later date.

I tend to think you put your lead program first. So putting a Ph1 ahead of a Ph3 says something about managements thinking. Again probably just emphasizes the importance of actually getting NASH started.